Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZD5148 for prevention of recurrent Clostridioides difficile infection
2025-521416-19-00Phase 2Authorised
- Sponsor
- AstraZeneca
- Start
- Mar 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 13
01
Overview
Phase 2, randomised, double-blind trial in Clostridioides difficile colitis (CDI) comparing AZD5148 with Placebo for AZD5148 (2 arms). Primary endpoint: First occurrence of recurrence of C. difficile infection. Planned start Mar 2026; status: authorised.
02
Drugs
azd5148
03
Conditions
Clostridioides difficile colitis (CDI)
Beyond the preview
Go deeper on 2025-521416-19-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-521416-19-00.